Ferroptosis in hepatocellular carcinoma: mechanisms and targeted therapy

被引:38
|
作者
Ajoolabady, Amir [1 ]
Tang, Daolin [2 ]
Kroemer, Guido [3 ,4 ,5 ]
Ren, Jun [1 ]
机构
[1] Fudan Univ, Shanghai Inst Cardiovasc Dis, Dept Cardiol, Zhongshan Hosp, Shanghai, Peoples R China
[2] UT Southwestern Med Ctr, Dept Surg, Dallas, TX 75390 USA
[3] Sorbonne Univ, Equipe Labellisee Ligue Canc, Inst Univ France, Ctr Rech Cordeliers,Univ Paris,Inserm U1138, Paris, France
[4] Inst Gustave Roussy, Metabol & Cell Biol Platforms, Villejuif, France
[5] Hop Europeen Georges Pompidou, AP HP, Pole Biol, Paris, France
基金
欧盟地平线“2020”;
关键词
CELL-DEATH; NONALCOHOLIC STEATOHEPATITIS; PROMOTES FERROPTOSIS; LIPID-PEROXIDATION; IRON; CANCER; METABOLISM; RESISTANCE; PROTEIN; IDENTIFICATION;
D O I
10.1038/s41416-022-01998-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hepatocellular carcinoma is the most prevalent form of primary liver cancer with a multifactorial aetiology comprising genetic, environmental, and behavioural factors. Evading cell death is a defining hallmark of hepatocellular carcinoma, underpinning tumour growth, progression, and therapy resistance. Ferroptosis is a form of nonapoptotic cell death driven by an array of cellular events, including intracellular iron overload, free radical production, lipid peroxidation and activation of various cell death effectors, ultimately leading to rupture of the plasma membrane. Although induction of ferroptosis is an emerging strategy to suppress hepatocellular carcinoma, malignant cells manage to develop adaptive mechanisms, conferring resistance to ferroptosis and ferroptosis-inducing drugs. Herein, we aim at elucidating molecular mechanisms and signalling pathways involved in ferroptosis and offer our opinions on druggable targets and new therapeutic strategy in an attempt to restrain the growth and progression of hepatocellular carcinoma through induction of ferroptotic cell death.
引用
收藏
页码:190 / 205
页数:16
相关论文
共 50 条
  • [21] Ferroptosis: a new promising target for hepatocellular carcinoma therapy
    Xu, Qiaoping
    Ren, Lanqi
    Ren, Ning
    Yang, Yibei
    Pan, Junjie
    Zheng, Yu
    Wang, Gang
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2023, 479 (10) : 2615 - 2636
  • [22] Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies
    Alqahtani, Ali
    Khan, Zubair
    Alloghbi, Abdurahman
    Ahmed, Tamer S. Said
    Ashraf, Mushtaq
    Hammouda, Danae M.
    MEDICINA-LITHUANIA, 2019, 55 (09):
  • [23] Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies
    Galun, Danijel
    Srdic-Rajic, Tatjana
    Bogdanovic, Aleksandar
    Loncar, Zlatibor
    Zuvela, Marinko
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2017, 4 : 93 - 103
  • [24] Targeted therapy of hepatocellular carcinoma: Present and future
    Chan, Stephen L.
    Yeo, Winnie
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 (05) : 862 - 872
  • [25] Hepatocellular Carcinoma: Targeted Therapy and Multidisciplinary Care
    Adler, Douglas G.
    PRACTICAL GASTROENTEROLOGY, 2011, 35 (10) : 56 - 56
  • [26] Latest developments in targeted therapy for hepatocellular carcinoma
    Montella, Liliana
    Addeo, Raffaele
    Caraglia, Michele
    Del Prete, Salvatore
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (10) : 1635 - 1646
  • [27] Molecular Genetics and Targeted Therapy in Hepatocellular Carcinoma
    Marks, Eric I.
    Yee, Nelson S.
    CURRENT CANCER DRUG TARGETS, 2016, 16 (01) : 53 - 70
  • [28] Targeted therapy for hepatocellular carcinoma: Challenges and opportunities
    Chen, Shuzhen
    Cao, Qiqi
    Wen, Wen
    Wang, Hongyang
    CANCER LETTERS, 2019, 460 : 1 - 9
  • [29] Hepatocellular Carcinoma: Targeted Therapy and Multidisciplinary Care
    Naugler, Willscott
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2011, 2 (02) : 122 - 122
  • [30] Molecular targeted therapy for advanced hepatocellular carcinoma
    Ying Chun Shen
    Chiun Hsu
    Ann Lii Cheng
    Targeted Oncology, 2007, 2 : 199 - 210